About Nupsala
Nupsala is a company based in Melton Mowbray (United Kingdom) founded in 2012. Nupsala has raised $192.6 thousand across 2 funding rounds from investors including Barclays. The company has 16 employees. Nupsala operates in a competitive market with competitors including Gallant, eQcell, Bioceltix, J-ARM and Vetherapy, among others.
- Headquarter Melton Mowbray, United Kingdom
- Employees 16
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nupsala.com
- Social LinkedIn X Facebook
- Legal Name Nupsala Limited
- Date of Incorporation 02 May, 2012
- Jurisdiction MELTON MOWBRAY, LEICESTERSHIRE, ENGLAND
- Total Equity Funding$192.6K (USD)
in 2 rounds
- Investors
- Employee Count16
Funding Insights of Nupsala
Nupsala has successfully raised a total of $192.6K across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $192,595
- Total Rounds 2
- First Round $192,595
(Jul 2018)
- Investors Count 1
All 2 funding rounds of Nupsala with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | – | Debt – Conventional | – | – | |
| Jul 2018 | $192,595 | Seed | $285,016 | – | – |
Last known valuation $285,016 (Jul 2018). 1 investors in total: 1 institutional.
Investors in Nupsala
Nupsala has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Barclays.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified financial services are provided across global markets. | 1690 | home.barclays | London, United Kingdom |
Investor details for Nupsala
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nupsala
5 people are tracked at Nupsala (1 in leadership, 4 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Greg McGarrell | CEO | Leadership |
Laura Carter | Account Manager | Team |
Rebecca Spurr | East Account Manager And Inside Sales Lead | Team |
Lisa Thomas | Senior Account Manager | Team |
Kizzy Bass | Inside Sales Lead Assistant | Team |
Complete people profiles for Nupsala
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nupsala
3 dated milestones of Nupsala across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Nupsala is founded.
- Funding First funding round of $193K.
- Funding Latest funding round, Debt – Conventional,.
Competitors of Nupsala
Nupsala operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gallant, eQcell, Bioceltix, J-ARM and Vetherapy, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gallant.com | 2018 | Los Angeles, United States | $61.46M | – | Stem cell storage for canine regenerative therapy is offered. | |
| eqcell.com | 2010 | Guelph, Canada | $4.6M | 8 | Stem cell therapies for animal health are developed. | |
| bioceltix.com | 2017 | Wroclaw, Poland | – | – | Developer of drugs for veterinary therapy | |
| j-arm.biz | 2006 | Osaka, Japan | – | – | Developer of lymphocyte therapy and stem cell therapy for dogs and cats | |
| vetherapy.co | 2015 | San Francisco, United States | $250,000 | – | Provider of stem cell therapies for pets | |
| revatis.com | 2013 | Luxemburg, United States | – | – | Undifferentiated muscle-derived stem cells are obtained via patented micro-biopsy technology. | |
| vetbiobank.com | 2011 | – | $450,237 | – | Veterinary regenerative medicine | |
| actcells.com | 2008 | San Diego, United States | $10.11M | – | Research and development of veterinary stem cell | |
| theracellinc.com | 2008 | Northridge, United States | $1.42M | – | Allograft solutions for spinal surgery are provided by TheraCell. |
Detailed competitors of Nupsala
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nupsala
The website of Nupsala (nupsala.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 35.3% vs previous month
Latest news on Nupsala
Complete news archive for Nupsala
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Nupsala
10 companies that operate in the same segment as Nupsala (Veterinary Digital Health), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Practice and prescription management software is provided for veterinary professionals. | 2010 | Portland, Oregon, United States | USD 291.64 M | – | – | |
Animal medicines, vaccines, and diagnostics are manufactured and supplied. | 2012 | Brussels, Brussels-capital Region, Belgium | – | – | – | |
Veterinary pharmacy services are delivered by VetSource to practices. | 2005 | Portland, Oregon, United States | USD 81.25 M | – | – | |
Animal health therapeutics are developed and supplied globally by Ceva. | 1999 | Libourne, Nouvelle-aquitaine, France | USD 214.35 M | – | – | |
Digital platform for pet insurance | 2020 | Stockholm, Sweden | USD 114.08 M | – | – | |
App based platform providing veterinary services and clinical management solutions for veterinarians | 2018 | Beverly Hills, California, United States | USD 58.81 M | – | – | |
Online client communication platform for veterinary doctors | 2013 | San Diego, California, United States | USD 14.11 M | USD 14.38 M | 1 | |
Virtual veterinary care is provided via an app platform. | 2018 | Los Angeles, California, United States | USD 210 M | – | 163 | |
Comprehensive customer engagement platform for veterinary clinics is provided. | 2015 | Austin, Texas, United States | USD 50.3 M | – | – | |
Veterinary appointments are booked via an online platform. | 2017 | Brooklyn, New York, United States | USD 243 M | – | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nupsala
Nupsala was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Nupsala is headquartered in Melton Mowbray, United Kingdom. It is registered at Melton Mowbray, England, United Kingdom.
Greg McGarrell is the current CEO of Nupsala.
Nupsala is a funded company, having raised a total of $192.6K across 2 funding rounds to date. The company's 1st funding round was a Seed of $192.6K, raised on Jul 2018.
Nupsala has 16 employees.
Nupsala was founded in 2012 in Melton Mowbray, United Kingdom, where operations as a veterinary wholesaler are conducted. Imported and hard-to-find pharmaceuticals and products are sourced and distributed to support animal health. Educational resources are provided for veterinary professionals and pet owners, with a focus on musculoskeletal treatments. Mobile lab services for regenerative medicine are also offered to facilitate specialized care.
Nupsala has 1 investor. Key investors include Barclays.
The valuation of Nupsala is $285.02K as of Jul 2018.
Nupsala operates through Nupsala Limited.